Ixit Tablet contains a combination of Flupenthixol (0.5 mg) and Melitracen (10 mg), formulated to provide therapeutic benefits in the management of depressive and anxiety disorders. Flupenthixol is a typical antipsychotic agent with anxiolytic and antidepressant properties, acting primarily by antagonizing dopamine D2 receptors, thereby modulating neurotransmitter activity in the central nervous system. Melitracen, a tricyclic antidepressant, enhances mood by inhibiting the reuptake of norepinephrine and serotonin, leading to increased synaptic concentrations of these neurotransmitters. The synergistic effect of these two active ingredients helps alleviate symptoms such as low mood, anxiety, and psychomotor retardation. Ixit Tablet is indicated for short-term treatment of mild to moderate depression accompanied by anxiety and psychosomatic disorders. It should be used under medical supervision, with caution advised in patients with a history of cardiovascular disease, glaucoma, or epilepsy. Common side effects may include dry mouth, dizziness, and gastrointestinal disturbances. Dosage should be individualized based on clinical response and tolerability. Ixit Tablet is contraindicated in patients with hypersensitivity to its components and should not be combined with monoamine oxidase inhibitors. Regular monitoring is recommended to assess therapeutic efficacy and detect any adverse reactions promptly.